Inclusion criteria
Reccurence, Cancer
ADVERSE EVENT, METASTASIS, LIVER METASTASES, ONCOLOGY, CANCER

Written informed consent and any locally required authorization obtained from the patient before performing any protocol-related procedures, including screening evaluationsMale or female age ≥18 years at time of study entryPerformance status of 0 or 1 according to the Eastern Cooperative Oncology Group and World Health OrganizationHistologically confirmed diagnoses of CRC with positive mutated KRas or NRasPatients with metastatic diseaseFirst-line metastatic disease or first-line after localized disease treated by local curative treatment, with or without adjuvant chemotherapy by FOLFOX. Reccurence after the last dose of adjuvant chemotherapy should be ≥ 6 months. Previous perioperative chemotherapy for resecable metastasis is not permitted.Life expectancy of more than 12 weeksAdequate normal organ and marrow function as defined below:Hemoglobin > 9.0 g dlAbsolute neutrophil count (ANC) > 1.5 × 10Platelet count > 100 × 10Serum bilirubin ≤1.5× the institutional upper limit of normal (ULN)AST (SGOT)/ALT (SGPT) ≤ 2.5× the institutional ULN unless liver metastases are present, in which case it must be ≤5× ULNPAL ≤ 5× institutional ULN unless liver metastases are present, in which case it must be ≤20× ULNAlbumin > 30 g LCreatinine < 1.5× institutional ULNSerum creatinine CL > 40 ml minWeight (kg) × (140–age) × 0.8572 × serum creatinine (mg dlTumor evaluation (computed tomography (CT) scan) in the previous 4 weeks with presence of at least one measurable lesion according to RECIST version 1.1At least 4 weeks since the last chemotherapy, immunotherapy or other drug therapy and/or radiotherapyRecovery to grade ≤1 from any AE derived from previous treatment according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0For principal study: willingness to provide consent for use of archived tissue with sufficient material available for analysis. For ancillary study: metastasis should be accessible to performed biopsy.Female patients must either be of non-reproductive potential (that is, post-menopausal by history: ≥60 years of age and no menses for ≥1 year without an alternative medical cause, or history of hysterectomy, or history of bilateral tubal ligation, or history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entryPatients must be affiliated with a social security systemPatient is willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations, including follow up